[
 {
  "content": "Copyright 2015 Federal Information and News Dispatch, Inc.\n         Securities and Exchange Commission Documents and Publications\n\n                                October 20, 2015\n\n\n\n\nBODY:\n\nOctober 16, 2015.\n\nIt appears to the Securities and Exchange Commission that there is a lack of\ncurrent and accurate information concerning the securities of Accentia\nBiopharmaceuticals, Inc. (CIK No. 1310094), a dissolved Florida corporation with\nits principal place of business listed as Tampa, Florida, with stock quoted ...\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (93%); OTC MARKETS GROUP INC (83%)",
  "section": [
   "REGULATORY DOCUMENTS"
  ],
  "headline": [
   "Accentia Biopharmaceuticals, Inc. and Biostem U.S. Corp., Order of\nSuspension of Trading"
  ],
  "length": [
   "351  words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2015  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                               September 23, 2015\n\n\n\n\nBODY:\n\n...\ncommon\u00a0stock\u00a0of\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 19 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMACEUTICALS: KCG Americas Reports 13.7% Stake"
  ],
  "length": [
   "323 words"
  ]
 },
 {
  "dateline": [
   "DUBLIN"
  ],
  "content": "Copyright 2015 Business Wire, Inc.\n                                 Business Wire\n\n                       August 7, 2015 Friday 12:40 PM GMT\n\n\n\n\nCOMPANY:\n\nROCHE HOLDING AG (84%); ACCENTIA BIOPHARMACEUTICALS INC (65%); JOHNSON & JOHNSON\n(64%); BRISTOL-MYERS SQUIBB CO (58%); GLAXOSMITHKLINE PLC (57%); CTI BIOPHARMA\nINC (...",
  "headline": [
   "Research and Markets: Follicular Lymphoma - Pipeline Review, H1 2015"
  ],
  "length": [
   "443 words"
  ]
 },
 {
  "dateline": [
   "DALLAS, July 28, 2015"
  ],
  "content": "Copyright 2015 PR Newswire Association LLC\n                              All Rights Reserved\n                                  PR Newswire\n\n                       July 28, 2015 Tuesday 2:46 PM EST\n\n\n\n\nBODY:\n\nCompanies discuss in this report includes AbbVie Inc., Accentia\nBiopharmaceuticals, Inc., Affimed Therapeutics AG, AmpliMed Corporation, Bayer\nAG, Bio-Path Holdings, Inc., Biocon Limited, Biogenomics Limited, ...\n\n...2015 33\n\nFollicular Lymphoma - Pipeline by AbbVie Inc., H1 2015 34\n\nFollicular Lymphoma - Pipeline by Accentia Biopharmaceuticals, Inc., H1 2015 35\n\nFollicular Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2015 36\n\nFollicular Lymphoma - ...\n\nCOMPANY:\n\n...BAYER AG (84%); JOHNSON & JOHNSON (82%); NOVARTIS AG (82%); CELGENE CORP\n(69%); BIOCON LTD (69%); ACCENTIA BIOPHARMACEUTICALS INC (69%); AFFIMED\nTHERAPEUTICS AG (69%); BIO-PATH HOLDINGS INC (69%); BOEHRINGER INGELHEIM GMBH\n(69%); ABBVIE ...",
  "headline": [
   "Follicular Lymphoma Therapeutic Pipeline Assesment and Development\nReview H1 2015",
   "RnRMarketResearch.com adds \"Follicular Lymphoma - Pipeline Review, H1 2015\" to\nits store. The report provides an overview of the Follicular Lymphoma's\ntherapeutic pipeline."
  ],
  "length": [
   "1246 words"
  ]
 },
 {
  "content": "Class Action Reporter\n  Copyright  1994 - 2015  Bankruptcy Creditors' Service, Inc. and Beard Group,\n                                      Inc.\n                              All Rights Reserved\n\n                             Class Action Reporter\n\n                                 June 25, 2015\n\n\n\n\nBODY:\n\n...\nof\u00a0Florida\u00a0(Tampa\u00a0Division)\u00a0against\u00a0Accentia\u00a0Biopharmaceuticals,\nInc.,\u00a0and\u00a0several\u00a0current\u00a0and\u00a0former\u00a0directors\u00a0and\u00a0officers\u00a0of\n...\n\nCOMPANY:\n\nBIODELIVERY SCIENCES INTERNATIONAL INC (95%); ACCENTIA BIOPHARMACEUTICALS INC\n(69%); BIOVEST INTERNATIONAL INC (69%)",
  "section": [
   "Vol. 17 ISSN: 1525-2272"
  ],
  "headline": [
   "BIODELIVERY SCIENCES: Class Action Settlement Approved by Court"
  ],
  "length": [
   "257 words"
  ]
 },
 {
  "dateline": [
   "DUBLIN"
  ],
  "content": "Copyright 2015 Business Wire, Inc.\n                                 Business Wire\n\n                        June 19, 2015 Friday 9:29 AM GMT\n\n\n\n\nCOMPANY:\n\n...LLP (84%); ORRICK HERRINGTON & SUTCLIFFE LLP (84%); FENNEMORE CRAIG PC (67%);\nFISHER & PHILLIPS LLP (67%); ACCENTIA BIOPHARMACEUTICALS INC (67%); ARNALL\nGOLDEN GREGORY LLP (67%); FOX ROTHSCHILD LLP (67%); JEFFER MANGELS BUTLER &\nMITCHELL LLP (...",
  "headline": [
   "Research and Markets: 2016 U.S Pharmaceutical Industry Attorney Rate\nReport Available Now for Analysis"
  ],
  "length": [
   "426 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2015  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 April 2, 2015\n\n\n\n\nBODY:\n\n...\nroughly\u00a06.96%\u00a0of\u00a0the\u00a0common\u00a0stock\u00a0of\u00a0Accentia\u00a0Biopharmaceuticals,\nInc.,\u00a0based\u00a0on\u00a0outstanding\u00a0shares\u00a0reported\u00a0in\u00a0the\u00a0Company's\u00a0Form\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 19 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMACEUTICALS: KCG Reports 6.96% Stake as of Dec. 31"
  ],
  "length": [
   "357 words"
  ]
 },
 {
  "content": "Class Action Reporter\n  Copyright  1994 - 2014  Bankruptcy Creditors' Service, Inc. and Beard Group,\n                                      Inc.\n                              All Rights Reserved\n\n                             Class Action Reporter\n\n                               December 23, 2014\n\n\n\n\nBODY:\n\n...\nOF\u00a0ACCENTIA\u00a0BIOPHARMACEUTICALS,\u00a0INC.,\u00a0AND/OR\u00a0THE\u00a0COMMON STOCK\u00a0OF\n...\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (84%); SHAPIRO HABER & URMY LLP (80%); BIOVEST\nINTERNATIONAL INC (71%)\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 16 ISSN: 1525-2272"
  ],
  "headline": [
   "ACCENTIA BIOPHARMA: January 26 Settlement Fairness Hearing Set"
  ],
  "length": [
   "552 words"
  ]
 },
 {
  "dateline": [
   "NEW YORK, Nov. 5, 2014"
  ],
  "content": "Copyright 2014 PR Newswire Association LLC\n                              All Rights Reserved\n                                  PR Newswire\n\n                     November 5, 2014 Wednesday 9:31 AM EST\n\n\n\n\nBODY:\n\n...DURING THE PERIOD FROM JULY 26, 2008, TO AND THROUGH AUGUST 14, 2012,\nINCLUSIVE, PURCHASED OR OTHERWISE ACQUIRED\u00a0 THE COMMON STOCK OF ACCENTIA\nBIOPHARMACEUTICALS, INC., AND/OR THE COMMON STOCK OF BIOVEST INTERNATIONAL,\nINC., AND WERE DAMAGED THEREBY (THE \"SETTLEMENT CLASS\").\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (93%); BIOVEST INTERNATIONAL INC (93%); SHAPIRO\nHABER & URMY LLP (85%)",
  "headline": [
   "Shapiro Haber & Urmy Announces Pendency and Proposed Settlement of\nClass Action Involving Accentia Biopharmaceuticals, Inc. (ABPI) and Biovest\nInternational, Inc., (BVTIQ) and Settlement Hearing"
  ],
  "length": [
   "590 words"
  ]
 },
 {
  "dateline": [
   "DUBLIN"
  ],
  "content": "Copyright 2014 Business Wire, Inc.\n                                                           Business Wire\n\n                                                 June 10, 2014 Tuesday 11:04 AM GMT\n\n\n\n\nBODY:\n\n...\nNovartis AG\nRigel Pharmaceuticals, Inc.\nGentium S.p.A.\nImmunomedics, Inc.\nMesoblast Limited\nSwedish Orphan Biovitrum AB\nAccentia Biopharmaceuticals, Inc.\nJazz Pharmaceuticals plc\nSoligenix, Inc.\nNeoStem, Inc.\nPluristem Therapeutics Inc.\nMediPost Co., Ltd.\nAlder Biopharmaceuticals ...\n\nCOMPANY:\n\n...TOBIRA THERAPEUTICS INC (66%); ALDER BIOPHARMACEUTICALS INC (66%); MESOBLAST LTD (66%); JAZZ PHARMACEUTICALS PLC (66%); ACCENTIA\nBIOPHARMACEUTICALS INC (66%); PLURISTEM THERAPEUTICS INC (66%); MEDIPOST CO LTD (66%); PHARMICELL CO LTD (65%)",
  "headline": [
   "Research and Markets: Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2014"
  ],
  "length": [
   "388 words"
  ]
 },
 {
  "content": "Class Action Reporter\n  Copyright  1994 - 2014  Bankruptcy Creditors' Service, Inc. and Beard Group,\n                                      Inc.\n                              All Rights Reserved\n\n                             Class Action Reporter\n\n                                  June 9, 2014\n\n\n\n\nBODY:\n\n...\ndeveloping\u00a0BiovaxID.\u00a0As\u00a0of\u00a0September\u00a030,\u00a02011,\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0owned\u00a0approximately\u00a062%\u00a0of\u00a0interest\u00a0in\n...",
  "section": [
   "Vol. 16 ISSN: 1525-2272"
  ],
  "headline": [
   "BIOVEST INT'L: Consolidated BiovaxID Suit Filed in January 21"
  ],
  "length": [
   "465 words"
  ]
 },
 {
  "dateline": [
   "DUBLIN"
  ],
  "content": "Copyright 2014 Business Wire, Inc.\n                                                           Business Wire\n\n                                                 June 4, 2014 Wednesday 2:04 PM GMT\n\n\n\n\nBODY:\n\n...in the report may be removed or altered based on the availability and relevance of data for the indicated disease.\n\nCompanies Mentioned:\nAccentia Biopharmaceuticals, Inc.\nAstellas Pharma Inc.\nBayer AG\nBiogen Idec Inc.\nCelgene Corporation\nCell Therapeutics, Inc.\nEmergent BioSolutions ...\n\nCOMPANY:\n\n...BIOGEN IDEC INC (84%); CTI BIOPHARMA INC (84%); CELGENE CORP (65%); ASTELLAS PHARMA INC (65%); ACCENTIA BIOPHARMACEUTICALS INC\n(65%); MERCK & CO INC (64%); INFINITY PHARMACEUTICALS INC (64%); PHARMACYCLICS INC (64%); INCYTE CORP (64%); ...",
  "headline": [
   "Research and Markets: Indolent Lymphoma - Pipeline Review, H1 2014"
  ],
  "length": [
   "421 words"
  ]
 },
 {
  "dateline": [
   "DUBLIN"
  ],
  "content": "Copyright 2014 Business Wire, Inc.\n                                                           Business Wire\n\n                                                 May 29, 2014 Thursday 7:04 PM GMT\n\n\n\n\nBODY:\n\n...\ntype\nLatest news and deals relating related to pipeline products\n\nCompanies Involved in Therapeutics Development\nShire Plc\nAccentia Biopharmaceuticals, Inc.\nAlexion Pharmaceuticals, Inc.\nAgios Pharmaceuticals, Inc.\n\nFor more information visit http://www.researchandmarkets.com/research/...\n\nCOMPANY:\n\nSHIRE PLC (84%); AGIOS PHARMACEUTICALS INC (63%); ALEXION PHARMACEUTICALS INC (63%); ACCENTIA BIOPHARMACEUTICALS INC (63%)",
  "headline": [
   "Research and Markets: Acquired (Autoimmune) Hemolytic Anemia Therapeutics Pipeline Report 2014"
  ],
  "length": [
   "420 words"
  ]
 },
 {
  "dateline": [
   "DUBLIN"
  ],
  "content": "Copyright 2014 Business Wire, Inc.\n                                                           Business Wire\n\n                                                 May 29, 2014 Thursday 10:08 AM GMT\n\n\n\n\nCOMPANY:\n\nBAYER AG (84%); BRISTOL-MYERS SQUIBB CO (84%); ROCHE HOLDING AG (84%); ACCENTIA BIOPHARMACEUTICALS INC (65%); CELGENE CORP (64%);\nMERCK & CO INC (64%); MILLENNIUM PHARMACEUTICALS INC (57%); GENMAB AS (53%); ABBVIE ...",
  "headline": [
   "Research and Markets: Follicular Lymphoma - Pipeline Review, H1 2014"
  ],
  "length": [
   "434 words"
  ]
 },
 {
  "content": "Class Action Reporter\n  Copyright  1994 - 2014  Bankruptcy Creditors' Service, Inc. and Beard Group,\n                                      Inc.\n                              All Rights Reserved\n\n                             Class Action Reporter\n\n                                 April 8, 2014\n\n\n\n\nBODY:\n\n...\nof\u00a0September\u00a030,\u00a02011,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\u00a0owned\n...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (95%); ACCENTIA BIOPHARMACEUTICALS INC (60%)",
  "section": [
   "Vol. 16 ISSN: 1525-2272"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Court Consolidated Suits v. Accentia"
  ],
  "length": [
   "431 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2014  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 April 7, 2014\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 18 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Incurs $2.1MM Net Loss in Dec. 31 Qtr."
  ],
  "length": [
   "464 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2014  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                               February 11, 2014\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 18 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Cherry Bekaert Raises Going Concern Doubt"
  ],
  "length": [
   "446 words"
  ]
 },
 {
  "content": "Copyright 2014 Strafford Publications, Inc.\n                              All Rights Reserved\n                        Securities Class Action Reporter\n\n                                January 31, 2014\n\n\n\n\nBODY:\n\nShareholders in Accentia Biopharmaceuticals Inc. sued the firm and certain of\nits officers, alleging securities fraud arising from material misrepresentations\nand omissions concerning the firm's business operations. The ...\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (93%); SHAPIRO HABER & URMY LLP (69%); STRAFFORD\nPUBLICATIONS INC (66%)",
  "section": [
   "Pg. 24"
  ],
  "headline": [
   "Lead plaintiff appointed in securities fraud class action against\npharmaceutical company",
   "Hill v. Accentia Biopharmaceuticals Inc., No. 13- 1945 (M.D. Fla. Dec. 4, 2013)"
  ],
  "length": [
   "311  words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2014  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                January 14, 2014\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Taps Robert Farrell as CFO"
  ],
  "length": [
   "677 words"
  ]
 },
 {
  "content": "Copyright 2013 Close-Up Media, Inc.\n                              All Rights Reserved\n\n\n                         Professional Services Close-Up\n\n                            December 15, 2013 Sunday\n\n\n\nBODY:\n\n...plc\n\nMedImmune LLC\n\nBioLineRx, Ltd.\n\nFibroGen, Inc.\n\narGentis Pharmaceuticals, LLC\n\nCelgene Corp.\n\nActive Biotech AB\n\nAccentia Biopharmaceuticals, Inc.\n\nDigna Biotech, S.L.\n\nMondobiotech Holding AG\n\nAngion Biomedica Corp.\n\nDaval International Ltd.\n\nResearch and Markets is a ...\n\nCOMPANY:\n\n...HOLDING AG (81%); GLAXOSMITHKLINE PLC (81%); GENZYME CORP (81%); BIOLINERX\nLTD (63%); FIBROGEN INC (63%); ACCENTIA BIOPHARMACEUTICALS INC (63%);\nTHERAMETRICS HOLDING AG (63%); DAVAL INTERNATIONAL LTD (63%); CELGENE CORP\n(63%); MEDIMMUNE INC (52%)",
  "headline": [
   "Research and Markets Offers Report: Systemic Sclerosis (Scleroderma) -\nPipeline Review, H2 2013"
  ],
  "length": [
   "452  words"
  ]
 },
 {
  "content": "Copyright 2013 Close-Up Media, Inc.\n                              All Rights Reserved\n\n\n                             Manufacturing Close-Up\n\n                            December 9, 2013 Monday\n\n\n\nBODY:\n\n...Sanofi-Aventis\n\nGlaxoSmithKline plc\n\nMedImmune\n\nBioLineRx\n\nFibroGen, Inc.\n\narGentis Pharmaceuticals\n\nCelgene Corp.\n\nActive Biotech AB\n\nAccentia Biopharmaceuticals, Inc.\n\nDigna Biotech, S.L.\n\nMondobiotech Holding AG\n\nAngion Biomedica Corp.\n\nDaval International\n\nReport information:\n\nhttp://www....\n\nCOMPANY:\n\n...HOLDING AG (82%); GLAXOSMITHKLINE PLC (82%); GENZYME CORP (82%); FIBROGEN INC\n(67%); CELGENE CORP (67%); ACCENTIA BIOPHARMACEUTICALS INC (66%); THERAMETRICS\nHOLDING AG (66%); BIOLINERX LTD (54%); MEDIMMUNE INC (54%)",
  "headline": [
   "Research and Markets Adds Report: 'Systemic Sclerosis (Scleroderma) -\nPipeline Review, H2 2013'"
  ],
  "length": [
   "293  words"
  ]
 },
 {
  "dateline": [
   "DUBLIN"
  ],
  "content": "Copyright 2013 Business Wire, Inc.\n                                                           Business Wire\n\n                                               November 6, 2013 Wednesday 9:11 AM GMT\n\n\n\n\nBODY:\n\n...Mentioned\n\nGilead Sciences, Inc.\n\nMillennium Pharmaceuticals, Inc.\n\nGenmab A/S\n\nCelgene Corporation\n\nOnyx Pharmaceuticals, Inc.\n\nAccentia Biopharmaceuticals, Inc.\n\nPharmacyclics, Inc.\n\nFor more information visit http://www.researchandmarkets.com/research/xg9br4/waldenstrom\n\nAbout Research and ...\n\nCOMPANY:\n\nMILLENNIUM PHARMACEUTICALS INC (68%); GENMAB AS (68%); GILEAD SCIENCES INC (68%); CELGENE CORP (67%); ACCENTIA BIOPHARMACEUTICALS\nINC (67%); ONYX PHARMACEUTICALS INC (67%); PHARMACYCLICS INC (67%)",
  "headline": [
   "Research and Markets: Waldenstrom Macroglobulinemia - Pipeline Review, H2 2013"
  ],
  "length": [
   "334 words"
  ]
 },
 {
  "content": "Copyright 2013 Close-Up Media, Inc.\n                              All Rights Reserved\n\n\n                             Manufacturing Close-Up\n\n                             October 4, 2013 Friday\n\n\n\nBODY:\n\n...Pharma Inc.\n\nEisai Co.\n\nGlenmark Pharmaceuticals\n\nCelgene Corp.\n\nMerck KGaA\n\nIMMUNOMEDICS, INC\n\nIdera Pharmaceuticals, Inc.\n\nAccentia Biopharmaceuticals, Inc.\n\nPharmacyclics, Inc.\n\nAbiogen Pharma S.p.A.\n\nCelentyx\n\nSemafore Pharmaceuticals, Inc.\n\nImmune System Therapeutics\n\nMirna Therapeutics, Inc....\n\nCOMPANY:\n\n...LTD (67%); MERCK KGAA (67%); CELGENE CORP (67%); INFINITY PHARMACEUTICALS INC\n(67%); PHARMACYCLICS INC (66%); ACCENTIA BIOPHARMACEUTICALS INC (66%); IDERA\nPHARMACEUTICALS INC (66%); MEDIMMUNE INC (55%); GLENMARK PHARMACEUTICALS LTD\n(54%)",
  "headline": [
   "Research and Markets Adds Report: B-Cell Lymphomas - Pipeline Review,\nH2 2013"
  ],
  "length": [
   "321  words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                October 2, 2013\n\n\n\n\nBODY:\n\n...\nDue\u00a0to\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.'s\u00a0lack\u00a0of\u00a0operating\u00a0funds\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMACEUTICALS: Delays Q2 10-Q for Lack of Funds"
  ],
  "length": [
   "260 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                               September 6, 2013\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: R. Osman Ownership at 26% as of July 18"
  ],
  "length": [
   "338 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                August 23, 2013\n\n\n\n\nBODY:\n\n...\nOn\u00a0June\u00a012,\u00a02013,\u00a0June\u00a018,\u00a02013,\u00a0and\u00a0July\u00a02,\u00a02013,\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.,\u00a0issued\u00a0three\u00a0separate\u00a0unsecured\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMACEUTICALS: Plan Declared Effective July 9"
  ],
  "length": [
   "961 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                August 21, 2013\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Emerges From Reorganization With New CEO"
  ],
  "length": [
   "959 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                August 19, 2013\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INT'L: Implements Plan, Lenders Take Over Ownership"
  ],
  "length": [
   "419 words"
  ]
 },
 {
  "dateline": [
   "DUBLIN"
  ],
  "content": "Copyright 2013 Business Wire, Inc.\n                                 Business Wire\n\n                      August 13, 2013 Tuesday 5:54 PM GMT\n\n\n\n\nBODY:\n\n...\nBioSolutions Inc.\nAstellas Pharma Inc.\nCephalon, Inc.\nCell Therapeutics, Inc.\nGenmab A/S\nCelgene Corporation\nAccentia Biopharmaceuticals, Inc.\n\nFor more information visit\nhttp://www.researchandmarkets.com/research/mxgwcm/indolent_lymphoma\n\nCOMPANY:\n\n...68%); ROCHE HOLDING AG (68%); GILEAD SCIENCES INC (68%); GENMAB AS (67%);\nEMERGENT BIOSOLUTIONS INC (67%); ACCENTIA BIOPHARMACEUTICALS INC (67%); CEPHALON\nINC (67%); CELGENE CORP (67%); ASTELLAS PHARMA INC (67%); CTI BIOPHARMA INC\n(67%)",
  "headline": [
   "Research and Markets: Indolent Lymphoma - Pipeline Review, H2 2012"
  ],
  "length": [
   "290 words"
  ]
 },
 {
  "dateline": [
   "DUBLIN"
  ],
  "content": "Copyright 2013 Business Wire, Inc.\n                                 Business Wire\n\n                       August 2, 2013 Friday 3:27 PM GMT\n\n\n\n\nBODY:\n\n...\nInc.\nSuperGen, Inc.\nTeva Pharmaceutical Industries Limited\nCell Therapeutics, Inc.\nCelgene Corporation\nOnyx Pharmaceuticals, Inc.\nAccentia Biopharmaceuticals, Inc.\nPharmacyclics, Inc.\nSenesco Technologies, Inc.\nMemgen, LLC.\nStemline Therapeutics, Inc.\nOnconova Therapeutics, Inc\nAdvancell\n\nFor ...\n\nCOMPANY:\n\n...PHARMACYCLICS INC (66%); ASTEX PHARMACEUTICALS INC (66%); CELGENE CORP (66%);\nTEVA PHARMACEUTICAL INDUSTRIES LTD (66%); ACCENTIA BIOPHARMACEUTICALS INC (66%);\nSTEMLINE THERAPEUTICS INC (66%); ONYX PHARMACEUTICALS INC (66%); ONCONOVA\nTHERAPEUTICS INC (66%); CTI BIOPHARMA ...",
  "headline": [
   "Research and Markets: Mantle Cell Lymphoma - Pipeline Review, H2 2013\nReport Featuring 22 Market Leaders"
  ],
  "length": [
   "334 words"
  ]
 },
 {
  "dateline": [
   "WASHINGTON, DC"
  ],
  "content": "Copyright 2013 States News Service\n                              States News Service\n\n                             July 16, 2013 Tuesday\n\n\n\n\n\nBODY:\n\n...sec.gov/edgar/searchedgar/companysearch.html.\n\nSTATE NAME OF ISSUER CODE 8K ITEM NO. DATE COMMENT ACCENTIA BIOPHARMACEUTICALS\nINC FL 1.01,2.03, 03/06/13 2.04,5.02,8.01 ACCESS MIDSTREAM PARTNERS LP DE\n8.01,9.01 07/15/13 ...",
  "headline": [
   "SEC NEWS DIGEST, ISSUE 2013-135, JULY 16, 2013"
  ],
  "length": [
   "3767 words"
  ],
  "byline": [
   "States News Service"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 June 26, 2013\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INT'L: Had $2.4-Mil. Net Loss in March 31 Qtr."
  ],
  "length": [
   "416 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 June 25, 2013\n\n\n\n\nBODY:\n\n...\nDue\u00a0to\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.'s\u00a0decrease\u00a0in\u00a0operating\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMACEUTICALS: Delays 10-Q for Limited Funds, Staff"
  ],
  "length": [
   "266 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 April 23, 2013\n\n\n\n\nBODY:\n\n...\nAccentia\u00a0Biopharmaceuticals,\u00a0Inc.'s\u00a0Board\u00a0of\u00a0Directors\u00a0accepted\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMACEUTICALS: Accepts Resignations of Directors"
  ],
  "length": [
   "365 words"
  ]
 },
 {
  "dateline": [
   "DUBLIN"
  ],
  "content": "Copyright 2013 Business Wire, Inc.\n                                 Business Wire\n\n                      April 18, 2013 Thursday 12:37 PM GMT\n\n\n\n\nBODY:\n\n...\nInc.\nNovartis AG\nPfizer Inc.\nSuperGen, Inc.\nCell Therapeutics, Inc.\nCelgene Corporation\nCelldex Therapeutics, Inc.\nAccentia Biopharmaceuticals, Inc.\nTelik, Inc.\nPharmacyclics, Inc.\nMemgen, LLC.\nSemafore Pharmaceuticals, Inc.\nStemline Therapeutics, Inc.\nOnconova Therapeutics, Inc\n...\n\nCOMPANY:\n\n...INC (67%); AMGEN INC (67%); GILEAD SCIENCES INC (67%); PHARMACYCLICS INC\n(66%); TELIK INC (66%); ACCENTIA BIOPHARMACEUTICALS INC (66%); CELLDEX\nTHERAPEUTICS INC (66%); ONCONOVA THERAPEUTICS INC (66%)",
  "headline": [
   "Research and Markets: Mantle Cell Lymphoma - Pipeline Review, H1 2013\nFeaturing 22 Major Companies"
  ],
  "length": [
   "344 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 April 15, 2013\n\n\n\n\nBODY:\n\n...\nBill\u00a0Rochelle,\u00a0the\u00a0bankruptcy\u00a0columnist\u00a0for\u00a0Bloomberg\u00a0News,\u00a0reports\u00a0that\nBiovest\u00a0and\u00a0majority\u00a0owner\u00a0Accentia\u00a0Biopharmaceuticals\u00a0Inc.\u00a0(Case\u00a0No.\u00a008-17795)\n\u00a0emerged\u00a0from\u00a0bankruptcy\u00a0reorganization\u00a0in\u00a0November\u00a02010\u00a0with\u00a0a\u00a0plan\u00a0to\u00a0pay\ncreditors\u00a0in\u00a0full\u00a0through\u00a0distributions\u00a0of\u00a0new stock.\n...",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INT'L: Returns to Chapter 11 with Another Debt-Swap Plan"
  ],
  "length": [
   "291 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 April 12, 2013\n\n\n\n\nBODY:\n\n...\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCESS PHARMACEUTICALS: Ayer Equity Stake at 4% as of Dec. 31"
  ],
  "length": [
   "569 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 April 12, 2013\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Incurs $3.3 Million Loss in Dec. 31 Qtr."
  ],
  "length": [
   "598 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 April 11, 2013\n\n\n\n\nBODY:\n\n...\nAccentia\u00a0Biopharmaceuticals,\u00a0Inc.,\u00a0filed\u00a0with\u00a0the\u00a0U.S.\u00a0Securities\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMACEUTICALS: Incurs $7.4MM Loss in Dec. 31 Qtr."
  ],
  "length": [
   "477 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 April 1, 2013\n\n\n\n\nBODY:\n\n...\nAccentia\u00a0Biopharmaceuticals,\u00a0Inc.'s\u00a0Board\u00a0of\u00a0Directors\u00a0accepted\nAccentia\u00a0Biopharmaceuticals,\u00a0Inc.,\u00a0is\u00a0biotechnology\u00a0company\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMACEUTICALS: S. Duffey Quits as CEO, Pres. & PEO"
  ],
  "length": [
   "701 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 April 1, 2013\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Laurus Owns 10% Equity Stake at Dec. 31"
  ],
  "length": [
   "617 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 March 29, 2013\n\n\n\n\nBODY:\n\n...\nAccentia\u00a0Biopharmaceuticals,\u00a0Inc.,\u00a0reported\u00a0a\u00a0net loss\u00a0of\nAccentia\u00a0Biopharmaceuticals,\u00a0Inc.,\u00a0is\u00a0biotechnology\u00a0company\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMA: Incurs $8.7-Mil. Net Loss in Fiscal Q1"
  ],
  "length": [
   "440 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 March 29, 2013\n\n\n\n\nBODY:\n\n...\nAs\u00a0of\u00a0Dec.\u00a031,\u00a02012,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.,\u00a0owned\n...",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Incurs $3.3-Mil. Net Loss in Fiscal Q1"
  ],
  "length": [
   "421 words"
  ]
 },
 {
  "content": "Copyright 2013 Times Publishing Company\n                              All Rights Reserved\n                          The Tampa Tribune (Florida)\n\n                             March 9, 2013 Saturday\n                                 FINAL EDITION\n\n\n\n\nBODY:\n\nTAMPA Several top executives of Accentia Biopharmaceuticals Inc. have left the\ncompany in the past week, including Douglas W. Calder, vice president of\nstrategic planning and capital markets, ...\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%); J C PENNEY CO INC (83%); MOTOROLA\nSOLUTIONS INC (54%); GOOGLE INC (54%)",
  "section": [
   "BUSINESS",
   "Pg. 3"
  ],
  "headline": [
   "Daily Briefing"
  ],
  "length": [
   "329 words"
  ]
 },
 {
  "dateline": [
   "WASHINGTON, DC"
  ],
  "content": "Copyright 2013 States News Service\n                              States News Service\n\n                              March 8, 2013 Friday\n\n\n\n\n\nBODY:\n\n...CORP OK 8.01,9.01 03/05/13 Acadia Healthcare Company, Inc. DE 8.01,9.01\n03/07/13 ACCENTIA BIOPHARMACEUTICALS INC FL 5.02,8.01 03/04/13 ACCURIDE CORP DE\n2.02,7.01,9.01 03/06/13 ACNB CORP PA ...",
  "headline": [
   "SEC NEWS DIGEST ISSUE 2013-45 MARCH 8, 2013"
  ],
  "length": [
   "7964 words"
  ],
  "byline": [
   "States News Service"
  ]
 },
 {
  "dateline": [
   "WASHINGTON, DC"
  ],
  "content": "Copyright 2013 States News Service\n                              States News Service\n\n                            February 25, 2013 Monday\n\n\n\n\n\nBODY:\n\n...sec.gov/edgar/searchedgar/companysearch.html.\n\nSTATE NAME OF ISSUER CODE 8K ITEM NO. DATE COMMENT\n--------------------------------------------------------------------------------\n--------- ACCENTIA BIOPHARMACEUTICALS INC FL 5.02 02/20/13 ACHILLION\nPHARMACEUTICALS INC DE 8.01,9.01 02/20/13 ADCARE HEALTH ...",
  "headline": [
   "SEC NEWS DIGEST ISSUE 2013-37 FEBRUARY 25, 2013"
  ],
  "length": [
   "4697 words"
  ],
  "byline": [
   "States News Service"
  ]
 },
 {
  "content": "Copyright 2013 Comtex News Network, Inc.\n                              All Rights Reserved\n Copyright 2013 Wall Street Horizon, Inc. The Earnings Calendar Company(sm) All\n                   rights reserved www.WallStreetHorizon.com\n\n                              Wall Street Horizon\n\n      This content is provided to LexisNexis by Comtex News Network, Inc.\n\n                     February 16, 2013 Saturday 8:37 PM EST\n\n\n\nBODY:\n\n...\nAccentia Biopharmaceuticals, Inc.\n...\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (93%)\n\nPUB-COMPANY:\n\nAccentia Biopharmaceuticals Inc\n\nCOMPANY-TERMS:\n\nAccentia Biopharmaceuticals Inc ABPIQ (OTC US) SIC: 2834 UNITED STATES",
  "headline": [
   "Accentia Biopharmaceuticals, Inc.Corporate Event Announcement Notice"
  ],
  "length": [
   "26  words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                               February 12, 2013\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INT'L: $11.7MM Net Loss in FY2012",
   "Defaults on $27MM Debt"
  ],
  "length": [
   "580 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                February 7, 2013\n\n\n\n\nBODY:\n\n...\nAccentia\u00a0Biopharmaceuticals,\u00a0Inc.,\u00a0filed\u00a0with\u00a0the\u00a0U.S.\u00a0Securities\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 17 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMACEUTICALS: Had $9.2MM Net Loss in Fiscal 2012"
  ],
  "length": [
   "539 words"
  ]
 },
 {
  "content": "Copyright 2013 Comtex News Network, Inc.\n                              All Rights Reserved\n Copyright 2013 Wall Street Horizon, Inc. The Earnings Calendar Company(sm) All\n                   rights reserved www.WallStreetHorizon.com\n\n                              Wall Street Horizon\n\n      This content is provided to LexisNexis by Comtex News Network, Inc.\n\n                      February 4, 2013 Monday 8:38 PM EST\n\n\n\nBODY:\n\n...\nAccentia Biopharmaceuticals, Inc. (ABPI.PK)\n...\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (93%)\n\nPUB-COMPANY:\n\nAccentia Biopharmaceuticals Inc\n\nCOMPANY-TERMS:\n\nAccentia Biopharmaceuticals Inc ABPIQ (OTC US) SIC: 2834 UNITED STATES",
  "headline": [
   "Accentia Biopharmaceuticals, Inc. (ABPI.PK) Corporate Event\nAnnouncement Notice"
  ],
  "length": [
   "28  words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                January 3, 2013\n\n\n\n\nBODY:\n\n...\nAccentia\u00a0Biopharmaceuticals,\u00a0Inc.,\u00a0failed\u00a0to\u00a0pay\u00a0an\u00a0aggregate\u00a0of\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMACEUTICALS: Misses $14.1-Mil. Debenture Payment"
  ],
  "length": [
   "387 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2013  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                January 3, 2013\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Has Standstill Pact with Corps, Valens"
  ],
  "length": [
   "918 words"
  ]
 },
 {
  "content": "Copyright 2012 The Deal, L.L.C.\n                              All Rights Reserved\n                               The Deal Pipeline\n\n                           December 29, 2012 Saturday\n\n\n\nBODY:\n\nCOMPANY WITH WARNING: 1940797 Accentia Biopharmaceuticals Inc.\n\nREFERENCE DATE: December 26, 2012\n\nWARNING SOURCE: Accounting firm\n\nWARNING COMPANY: 2032792 Cherry, Bekaert & Holland ...\n\n...loss\nWorking capital deficit\nBurdensome debt\n\nDESCRIPTION: Cherry, Bekaert & Holland LLP expressed substantial doubt about\nAccentia Biopharmaceuticals Inc.'s ability to continue as a going concern,\npointing to net losses, a working capital deficit and burdensome debt.\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (93%); CHERRY BEKAERT & HOLLAND LLP (93%)",
  "headline": [
   "Bankruptcy Warning"
  ],
  "length": [
   "76 words"
  ]
 },
 {
  "content": "Copyright 2012 Comtex News Network, Inc.\n                              All Rights Reserved\n Copyright 2012 Wall Street Horizon, Inc. The Earnings Calendar Company(sm) All\n                   rights reserved www.WallStreetHorizon.com\n\n                              Wall Street Horizon\n\n      This content is provided to LexisNexis by Comtex News Network, Inc.\n\n                    December 12, 2012 Wednesday 8:40 PM EST\n\n\n\nBODY:\n\n...\nAccentia Biopharmaceuticals, Inc. (ABPI.PK)\n...\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (93%)\n\nPUB-COMPANY:\n\nAccentia Biopharmaceuticals Inc\n\nCOMPANY-TERMS:\n\nAccentia Biopharmaceuticals Inc ABPIQ (OTC US) SIC: 2834 UNITED STATES",
  "headline": [
   "Accentia Biopharmaceuticals, Inc. (ABPI.PK) Corporate Event\nAnnouncement Notice"
  ],
  "length": [
   "28  words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                                           Business Wire\n\n                                                December 4, 2012 Tuesday 7:45 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB: \"BVTI\"), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: \"ABPI\"), today\nannounced that Biovest will present at the Lymphoma Coalition's annual patient advocacy event leading ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker symbol \"BVTI\", and is a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (93%)",
  "headline": [
   "Biovest to Present BiovaxID(TM) Cancer Vaccine Update at Lymphoma Coalition Patient Advocacy Event prior to ASH Meeting"
  ],
  "length": [
   "845 words"
  ]
 },
 {
  "dateline": [
   "WASHINGTON, DC"
  ],
  "content": "Copyright 2012 States News Service\n                              States News Service\n\n                            November 26, 2012 Monday\n\n\n\n\n\nBODY:\n\n...sec.gov/edgar/searchedgar/companysearch.html.\n\nSTATE NAME OF ISSUER CODE 8K ITEM NO. DATE COMMENT\n--------------------------------------------------------------------------------\n--------- ACCENTIA BIOPHARMACEUTICALS INC FL 2.04 11/17/12 AMERICAN\nINTERNATIONAL GROUP INC DE 8.01,9.01 11/21/12 American ...",
  "headline": [
   "SEC NEWS DIGEST ISSUE 2012-225 NOVEMBER 26, 2012"
  ],
  "length": [
   "3300 words"
  ],
  "byline": [
   "States News Service"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                               November 22, 2012\n\n\n\n\nBODY:\n\n...\nowned\u00a0subsidiary\u00a0of\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\u00a0\u00a0As\u00a0a\u00a0result\nBecause\u00a0the\u00a0Additional\u00a0Loan\u00a0will\u00a0materially\u00a0benefit\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.,\u00a0and\u00a0as\u00a0an\u00a0inducement\u00a0for\u00a0Corps\u00a0Real\u00a0to\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMACEUTICALS: Grants Corps Real New 5.5MM Warrant"
  ],
  "length": [
   "726 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                               November 22, 2012\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Corps Real Invests Additional $708,000"
  ],
  "length": [
   "390 words"
  ]
 },
 {
  "content": "Copyright 2012 Comtex News Network, Inc.\n                              All Rights Reserved\n Copyright 2012 Wall Street Horizon, Inc. The Earnings Calendar Company(sm) All\n                   rights reserved www.WallStreetHorizon.com\n\n                              Wall Street Horizon\n\n      This content is provided to LexisNexis by Comtex News Network, Inc.\n\n                    November 21, 2012 Wednesday 8:38 PM EST\n\n\n\nBODY:\n\n...\nAccentia Biopharmaceuticals, Inc. (ABPI.PK)\n...\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (93%)\n\nPUB-COMPANY:\n\nAccentia Biopharmaceuticals Inc\n\nCOMPANY-TERMS:\n\nAccentia Biopharmaceuticals Inc ABPIQ (OTC US) SIC: 2834 UNITED STATES",
  "headline": [
   "Accentia Biopharmaceuticals, Inc. (ABPI.PK) Corporate Event\nAnnouncement Notice"
  ],
  "length": [
   "28  words"
  ]
 },
 {
  "dateline": [
   "WASHINGTON, DC"
  ],
  "content": "Copyright 2012 States News Service\n                              States News Service\n\n                            October 16, 2012 Tuesday\n\n\n\n\n\nBODY:\n\n...ISSUER CODE 8K ITEM NO. DATE COMMENT\n\n--------------------------------------------------------------------------------\n---------\n\nA123 SYSTEMS, INC. DE 1.01,2.06,8.01,9.01 10/11/12 ACCENTIA BIOPHARMACEUTICALS\nINC FL 1.01,2.03,3.02 10/09/12 Activision Blizzard, Inc. DE 5.02 10/09/12\nADVANCED ENERGY ...",
  "headline": [
   "SEC NEWS DIGEST ISSUE 2012-200 OCTOBER 16, 2012"
  ],
  "length": [
   "2657 words"
  ],
  "byline": [
   "States News Service"
  ]
 },
 {
  "dateline": [
   "ALBANY, New York, October 8, 2012"
  ],
  "content": "Copyright 2012 PR Newswire Association LLC\n                              All Rights Reserved\n                                  PR Newswire\n\n                       October 8, 2012 Monday 6:00 AM EST\n\n\n\n\nBODY:\n\n...team of industry experts.\n\nRelated Reports\n\nEiger BioPharmaceuticals, Inc\n\nRegeneRx Biopharmaceuticals, Inc\n\nSK Biopharmaceuticals Co., Ltd\n\nAccentia Biopharmaceuticals, Inc\n\nNabi Biopharmaceuticals\n\nLeading Contract Manufacturing Organizations (CMOs) offer manufacturing\nfunctions both upstream and downstream equally. In ...\n\nCOMPANY:\n\nREGENERX BIOPHARMACEUTICALS INC (68%); ACCENTIA BIOPHARMACEUTICALS INC (68%);\nBIOTA PHARMACEUTICALS INC (55%)",
  "headline": [
   "MarketResearchReports.Biz - Biopharmaceutical Manufacturing in India,\nChina and South Korea - Regulatory Framework, Infrastructure Support and\nDiscovery Funding Create an Environment Conducive to Growth - New Market\nResearch Report"
  ],
  "length": [
   "937 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                               September 24, 2012\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Incurs $1.7-Mil. Net Loss in June 30 Qtr."
  ],
  "length": [
   "437 words"
  ]
 },
 {
  "content": "Copyright 2012 Espicom Business Intelligence\n                              All Rights Reserved\n                                Cancer Drug News\n\n                               September 21, 2012\n\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "section": [
   "NEWS"
  ],
  "headline": [
   "Biovest conducts meeting with EMA for BiovaxID"
  ],
  "length": [
   "177  words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                    September 20, 2012 Thursday 12:15 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today reported milestone\nachievements advancing BiovaxID(TM), Biovest's personalized cancer vaccine for\nthe treatment of ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia Biopharmaceuticals\n, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "headline": [
   "Biovest Conducts Meeting with EMA Advancing Process to Seek EU\nApproval for Cancer Vaccine",
   "Key Contributor to Human Genome Project Joins Scientific Advisory Board"
  ],
  "length": [
   "1050 words"
  ]
 },
 {
  "content": "Copyright 2012 Comtex News Network, Inc.\n                              All Rights Reserved\n                       Copyright 2012 TheFlyOnTheWall.com\n\n                              Theflyonthewall.com\n\n      This content is provided to LexisNexis by Comtex News Network, Inc.\n\n                    September 20, 2012 Thursday 8:22 AM EST\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)\n\nPUB-COMPANY:\n\nAccentia Biopharmaceuticals Inc; Accentia Biopharmaceuticals Inc\n\nCOMPANY-TERMS:\n\nAccentia Biopharmaceuticals Inc ABPI (NASDAQ GM) SEDOL: 2964955 SIC: 2834 UNITED\nSTATES",
  "headline": [
   "BVTI, ABPI: Recommendations"
  ],
  "length": [
   "141  words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                    September 11, 2012 Tuesday 11:45 AM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that it\nappointed Sattva S. Neelapu, M.D., Associate Professor, Department of\nLymphoma/Myeloma, ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia Biopharmaceuticals\n, Inc. (OTCQB: ABPI).\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nM D ANDERSON CANCER CENTER (93%); BIOVEST INTERNATIONAL INC (93%); ACCENTIA\nBIOPHARMACEUTICALS INC (91%)",
  "headline": [
   "Biovest Names Lymphoma Key Opinion Leader from MD Anderson Cancer\nCenter to Scientific Advisory Board",
   "Company to Present on its BiovaxID(TM) Personalized Cancer Vaccine on 'World\nLymphoma Awareness Day'"
  ],
  "length": [
   "1072 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                August 10, 2012\n\n\n\n\nBODY:\n\n...\nAccentia\u00a0Biopharmaceuticals,\u00a0Inc.,\u00a0filed\u00a0with\u00a0the\u00a0U.S.\u00a0Securities\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMACEUTICALS: Registers 1.6 Million Common Shares"
  ],
  "length": [
   "550 words"
  ]
 },
 {
  "content": "Copyright 2012 Comtex News Network, Inc.\n                              All Rights Reserved\n Copyright 2012 Wall Street Horizon, Inc. The Earnings Calendar Company(sm) All\n                   rights reserved www.WallStreetHorizon.com\n\n                              Wall Street Horizon\n\n      This content is provided to LexisNexis by Comtex News Network, Inc.\n\n                       August 7, 2012 Tuesday 9:24 PM EST\n\n\n\nBODY:\n\n...\nAccentia Biopharmaceuticals, Inc. (ABPI.PK)\n...\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (93%)\n\nPUB-COMPANY:\n\nAccentia Biopharmaceuticals Inc\n\nCOMPANY-TERMS:\n\nAccentia Biopharmaceuticals Inc ABPIQ (OTC US) SIC: 2834 UNITED STATES",
  "headline": [
   "Accentia Biopharmaceuticals, Inc. (ABPI.PK) Corporate Event\nAnnouncement Notice"
  ],
  "length": [
   "28  words"
  ]
 },
 {
  "content": "Copyright 2012 Espicom Business Intelligence\n                              All Rights Reserved\n                                Cancer Drug News\n\n                                 July 31, 2012\n\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "section": [
   "NEWS"
  ],
  "headline": [
   "Biovest advances process seeking EU approval for BiovaxID"
  ],
  "length": [
   "80  words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                        July 30, 2012 Monday 1:45 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that the\nEuropean Medicines Agency (EMA) has notified Biovest regarding the official\ndesignation of the Rapporteur and Co-...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia Biopharmaceuticals\n, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (91%);\nGLAXOSMITHKLINE PLC (53%); NOVARTIS AG (53%)",
  "headline": [
   "Biovest Advances Process Seeking European Marketing Approval for\nBiovaxID(TM) Personalized Lymphoma Vaccine"
  ],
  "length": [
   "1059 words"
  ]
 },
 {
  "content": "Copyright 2012 Comtex News Network, Inc.\n                              All Rights Reserved\n                       Copyright 2012 TheFlyOnTheWall.com\n\n                              Theflyonthewall.com\n\n      This content is provided to LexisNexis by Comtex News Network, Inc.\n\n                        July 30, 2012 Monday 9:47 AM EST\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)\n\nPUB-COMPANY:\n\nAccentia Biopharmaceuticals Inc\n\nCOMPANY-TERMS:\n\nAccentia Biopharmaceuticals Inc ABPIQ (OTC US) SEDOL: 2964955 SIC: 2834 UNITED\nSTATES",
  "headline": [
   "BVTI: Hot Stocks"
  ],
  "length": [
   "171  words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 July 30, 2012\n\n\n\n\nBODY:\n\n...\nAccentia\u00a0Biopharmaceuticals,\u00a0Inc.,\u00a0sold\u00a0an\u00a0aggregate\u00a0of\u00a01,071,432\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMACEUTICALS: Sells $1.1-Mil. Units for $225,000"
  ],
  "length": [
   "494 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 July 27, 2012\n\n\n\n\nBODY:\n\n...\nAccentia\u00a0Biopharmaceuticals,\u00a0Inc.,\u00a0entered\u00a0into\u00a0a\u00a0convertible\u00a0debt\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMA: Has $1.5MM Financing Agreement with Pabeti"
  ],
  "length": [
   "931 words"
  ]
 },
 {
  "content": "Copyright 2012 Close-Up Media, Inc.\n                              All Rights Reserved\n\n\n                                 Wireless News\n\n                             July 21, 2012 Saturday\n\n\n\nBODY:\n\nBiovest International, Inc., a majority-owned subsidiary of Accentia\nBiopharmaceuticals, Inc., announced that in response to Biovest's notice of\nintent to file for marketing approval previously submitted to the European\nMedicines Agency (...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "headline": [
   "EMA Confirms Biovest's Eligibility to Seek EU Marketing Approval for\nBiovaxID Cancer Vaccine as Orphan Drug"
  ],
  "length": [
   "434  words"
  ]
 },
 {
  "content": "Copyright 2012 Espicom Business Intelligence\n                              All Rights Reserved\n                            Anti-Infective Drug News\n\n                                 July 20, 2012\n\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "section": [
   "NEWS"
  ],
  "headline": [
   "Study positions Biovest bioreactor as potential novel viral vaccine\nmanufacturing platform"
  ],
  "length": [
   "209  words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 July 20, 2012\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Delays Note Interest Payment Until Nov."
  ],
  "length": [
   "456 words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                      July 19, 2012 Thursday 12:15 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that the Max\nPlanck Society recently hosted a research seminar in Berlin, Germany ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia Biopharmaceuticals\n, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "headline": [
   "Max Planck Institute Presents Study Positioning Biovest Bioreactor\nSystems as Potential Novel Viral Vaccine Manufacturing Platform"
  ],
  "length": [
   "1283 words"
  ]
 },
 {
  "content": "Copyright 2012 Comtex News Network, Inc.\n                              All Rights Reserved\n                       Copyright 2012 TheFlyOnTheWall.com\n\n                              Theflyonthewall.com\n\n      This content is provided to LexisNexis by Comtex News Network, Inc.\n\n                       July 19, 2012 Thursday 8:19 AM EST\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)\n\nPUB-COMPANY:\n\nAccentia Biopharmaceuticals Inc; Accentia Biopharmaceuticals Inc\n\nCOMPANY-TERMS:\n\nAccentia Biopharmaceuticals Inc ABPI (NASDAQ GM) SEDOL: 2964955 SIC: 2834 UNITED\nSTATES",
  "headline": [
   "BVTI, ABPI: Hot Stocks"
  ],
  "length": [
   "84  words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                      July 18, 2012 Wednesday 12:45 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB:BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB:ABPI), today announced that a special\nreport published by FierceBiotech highlights Biovest's BiovaxID\u00ae personalized\n...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia Biopharmaceuticals\n, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "headline": [
   "Biovest's BiovaxID\u00ae Lymphoma Vaccine Featured in FierceBiotech Cancer\nImmunotherapy Special Report"
  ],
  "length": [
   "984 words"
  ]
 },
 {
  "content": "Copyright 2012 Espicom Business Intelligence\n                              All Rights Reserved\n                                Cancer Drug News\n\n                                 July 13, 2012\n\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "section": [
   "NEWS"
  ],
  "headline": [
   "Biovest eligible to submit BiovaxID MAA to EMA"
  ],
  "length": [
   "62  words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                       July 12, 2012 Thursday 1:45 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that in\nresponse to Biovest's notice of intent to file for marketing approval previously\nsubmitted to the ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia Biopharmaceuticals\n, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "headline": [
   "Biovest's Eligibility to Seek EU Marketing Approval for its BiovaxID\nCancer Vaccine as Orphan Drug Confirmed by EMA",
   "Company's Biomanufacturing Capabilities Featured in Article Published in GEN"
  ],
  "length": [
   "1020 words"
  ]
 },
 {
  "content": "Copyright 2012 Comtex News Network, Inc.\n                              All Rights Reserved\n                       Copyright 2012 TheFlyOnTheWall.com\n\n                              Theflyonthewall.com\n\n      This content is provided to LexisNexis by Comtex News Network, Inc.\n\n                       July 12, 2012 Thursday 9:47 AM EST\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)\n\nPUB-COMPANY:\n\nAccentia Biopharmaceuticals Inc; Accentia Biopharmaceuticals Inc\n\nCOMPANY-TERMS:\n\nAccentia Biopharmaceuticals Inc ABPI (NASDAQ GM) SEDOL: 2964955 SIC: 2834 UNITED\nSTATES",
  "headline": [
   "BVTI, ABPI: Hot Stocks"
  ],
  "length": [
   "115  words"
  ]
 },
 {
  "content": "Copyright 2012 Comtex News Network, Inc.\n                              All Rights Reserved\n Copyright 2012 Wall Street Horizon, Inc. The Earnings Calendar Company(sm) All\n                   rights reserved www.WallStreetHorizon.com\n\n                              Wall Street Horizon\n\n      This content is provided to LexisNexis by Comtex News Network, Inc.\n\n                       July 10, 2012 Tuesday 8:36 PM EST\n\n\n\nBODY:\n\n...\nAccentia Biopharmaceuticals, Inc. (ABPI.PK)\n...\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (93%)\n\nPUB-COMPANY:\n\nAccentia Biopharmaceuticals Inc\n\nCOMPANY-TERMS:\n\nAccentia Biopharmaceuticals Inc ABPIQ (OTC US) SIC: 2834 UNITED STATES",
  "headline": [
   "Accentia Biopharmaceuticals, Inc. (ABPI.PK) Corporate Event\nAnnouncement Notice"
  ],
  "length": [
   "28  words"
  ]
 },
 {
  "content": "Copyright 2012 Federal Information and News Dispatch, Inc.\n         Securities and Exchange Commission Documents and Publications\n\n                                 June 28, 2012\n\n\n\nBODY:\n\n...433-8211 - 0 ($1,165,943,322.00) Equity, (File 333-182374 - Jun. 27) (BR.\n06C)\n\nS-1 ACCENTIA BIOPHARMACEUTICALS INC, 324 SOUTH HYDE PARK AVE, SUITE 350, TAMPA,\nFL, 33606, 813.864.2554 - 1,607,148 ($369,645.00) Equity, (...",
  "headline": [
   "News Digest",
   "SECURITIES ACT REGISTRATIONS"
  ],
  "length": [
   "625  words"
  ]
 },
 {
  "dateline": [
   "WASHINGTON, DC"
  ],
  "content": "Copyright 2012 States News Service\n                              States News Service\n\n                             June 28, 2012 Thursday\n\n\n\n\n\nBODY:\n\n...433-8211 - 0 ($1,165,943,322.00) Equity, (File 333-182374 - Jun. 27) (BR.\n06C) S-1 ACCENTIA BIOPHARMACEUTICALS INC, 324 SOUTH HYDE PARK AVE, SUITE 350,\nTAMPA, FL, 33606, 813.864.2554 - 1,607,148 ($369,645.00) Equity, (...",
  "headline": [
   "ENFORCEMENT PROCEEDINGS SEC CHARGES PHILIP A. FALCONE AND HARBINGER\nCHARGED WITH SECURITIES FRAUD"
  ],
  "length": [
   "8345 words"
  ],
  "byline": [
   "States News Service"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 June 25, 2012\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Incurs $5.9-Mil. Net Loss in March 31 Qtr."
  ],
  "length": [
   "438 words"
  ]
 },
 {
  "dateline": [
   "WASHINGTON, DC"
  ],
  "content": "Copyright 2012 States News Service\n                              States News Service\n\n                              June 22, 2012 Friday\n\n\n\n\n\nBODY:\n\n...CO /DE/ DE 7.01,9.01 06/20/12 ACACIA RESEARCH CORP DE 8.01 06/20/12 ACCENTIA\nBIOPHARMACEUTICALS INC FL 1.01,3.02,9.01 06/15/12 ADA-ES INC CO 4.02,8.01,9.01\n06/20/12 ADCARE HEALTH ...",
  "headline": [
   "COMMISSION ANNOUNCEMENTS COMMISSION MEETINGS CLOSED MEETING ON\nTHURSDAY, JUNE 28, 2012 AT 1:00 P.M."
  ],
  "length": [
   "3988 words"
  ],
  "byline": [
   "States News Service"
  ]
 },
 {
  "content": "Copyright 2012 Espicom Business Intelligence\n                              All Rights Reserved\n                                Cancer Drug News\n\n                                  June 8, 2012\n\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (72%)",
  "section": [
   "NEWS"
  ],
  "headline": [
   "BiovaxID study shows OS/time-to-next treatment benefits for MCL\npatients"
  ],
  "length": [
   "429  words"
  ]
 },
 {
  "dateline": [
   "WASHINGTON, DC"
  ],
  "content": "Copyright 2012 States News Service\n                              States News Service\n\n                              June 8, 2012 Friday\n\n\n\n\n\nBODY:\n\n...ENTERTAINMENT INC NY 8.01,9.01 06/07/12 Abtech Holdings, Inc. NV 7.01,9.01\n06/06/12 ACCENTIA BIOPHARMACEUTICALS INC FL 1.01,2.03,3.02,9.01 06/01/12 ACORDA\nTHERAPEUTICS INC 5.07 06/06/12 ADCARE HEALTH SYSTEMS ...",
  "headline": [
   "SEC NEWS DIGEST ISSUE 2012-111 JUNE 8, 2012"
  ],
  "length": [
   "4355 words"
  ],
  "byline": [
   "States News Service"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                       June 7, 2012 Thursday 12:15 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that the U.S.\nNational Cancer Institute (NCI) presented long-term (median 10-year ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia\nBiopharmaceuticals, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (91%); M D\nANDERSON CANCER CENTER (53%)",
  "headline": [
   "NCI Study Demonstrates Significant Overall Survival and\nTime-to-Next-Treatment Benefits for BiovaxID\u00ae Cancer Vaccine Following\nRituximab-Chemotherapy in Mantle Cell Lymphoma Study",
   "Results presented at ASCO and highlighted in article published in GEN"
  ],
  "length": [
   "1442 words"
  ]
 },
 {
  "content": "Copyright 2012 Comtex News Network, Inc.\n                              All Rights Reserved\n                       Copyright 2012 TheFlyOnTheWall.com\n\n                              Theflyonthewall.com\n\n      This content is provided to LexisNexis by Comtex News Network, Inc.\n\n                       June 7, 2012 Thursday 8:18 AM EST\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)\n\nPUB-COMPANY:\n\nAccentia Biopharmaceuticals Inc; Accentia Biopharmaceuticals Inc\n\nCOMPANY-TERMS:\n\nAccentia Biopharmaceuticals Inc ABPI (NASDAQ GM) SEDOL: 2964955 SIC: 2834 UNITED\nSTATES",
  "headline": [
   "BVTI, ABPI: Hot Stocks"
  ],
  "length": [
   "127  words"
  ]
 },
 {
  "content": "Copyright 2012 Close-Up Media, Inc.\n                              All Rights Reserved\n\n\n\n                            Health & Beauty Close-up\n\n                             May 31, 2012 Thursday\n\n\n\nBODY:\n\nBiovest International, Inc., a majority-owned subsidiary of Accentia\nBiopharmaceuticals, Inc., announced that Biovest has named Eduardo M. Sotomayor,\nM.D. to its Scientific Advisory Board (SAB).\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "headline": [
   "Biovest Elects Dr. Eduardo Sotomayor to Its Scientific Advisory Board"
  ],
  "length": [
   "326  words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                        May 29, 2012 Tuesday 5:30 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that Biovest\nhas named Eduardo M. Sotomayor, M.D. to its Scientific Advisory Board (SAB). The\nBiovest ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia Biopharmaceuticals\n, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (93%)",
  "headline": [
   "Biovest Names Dr. Eduardo Sotomayor, Chair of Dept of Malignant\nHematology at Moffitt Cancer Center, to its Scientific Advisory Board"
  ],
  "length": [
   "780 words"
  ]
 },
 {
  "content": "Copyright 2012 Close-Up Media, Inc.\n                              All Rights Reserved\n\n\n                         Professional Services Close-Up\n\n                              May 28, 2012 Monday\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "headline": [
   "Biovest International Rolls Out BiovaxID Phase II Mantle Cell Lymphoma\nClinical Trial Abstract"
  ],
  "length": [
   "288  words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                  May 25, 2012\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Board OKs Increase in Executives' Salaries"
  ],
  "length": [
   "594 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                  May 23, 2012\n\n\n\n\nBODY:\n\n...\nAccentia\u00a0Biopharmaceuticals,\u00a0Inc.,\u00a0filed\u00a0an\u00a0amendment\u00a0to\u00a0its\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMA: Board OK's Executive Salaries with Condition"
  ],
  "length": [
   "600 words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                        May 22, 2012 Tuesday 6:15 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that an article\nwas published in Scrip Intelligence reporting on Biovest's regulatory plans ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia Biopharmaceuticals\n, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "headline": [
   "BiovaxID\u00ae Personalized Lymphoma Vaccine is Featured in Article\nPublished in Scrip Intelligence"
  ],
  "length": [
   "917 words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                        May 18, 2012 Friday 2:24 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that an\nabstract reporting new data from the BiovaxID\u00ae Phase II mantle cell ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia Biopharmaceuticals\n, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "headline": [
   "Biovest Announces BiovaxID\u00ae ASCO Abstract Available On-line",
   "NCI to\nPresent Cancer Vaccine Data from Mantle Cell Lymphoma Study"
  ],
  "length": [
   "1019 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                  May 18, 2012\n\n\n\n\nBODY:\n\n...\nAccentia\u00a0Biopharmaceuticals,\u00a0Inc.,\u00a0is\u00a0seeking\u00a0marketing\u00a0approval\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: To Seek Marketing Approval for BiovaxID"
  ],
  "length": [
   "1139 words"
  ]
 },
 {
  "content": "Copyright 2012 Comtex News Network, Inc.\n                              All Rights Reserved\n Copyright 2012 Wall Street Horizon, Inc. The Earnings Calendar Company(sm) All\n                   rights reserved www.WallStreetHorizon.com\n\n                              Wall Street Horizon\n\n      This content is provided to LexisNexis by Comtex News Network, Inc.\n\n                       May 17, 2012 Thursday 8:36 PM EST\n\n\n\nBODY:\n\n...\nAccentia Biopharmaceuticals, Inc. (ABPI.PK)\n...\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (93%)\n\nPUB-COMPANY:\n\nAccentia Biopharmaceuticals Inc\n\nCOMPANY-TERMS:\n\nAccentia Biopharmaceuticals Inc ABPIQ (OTC US) SIC: 2834 UNITED STATES",
  "headline": [
   "Accentia Biopharmaceuticals, Inc. (ABPI.PK) Corporate Event\nAnnouncement Notice"
  ],
  "length": [
   "28  words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                       May 16, 2012 Wednesday 1:45 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB:BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB:ABPI), today announced that Biovest has\nretained Ferghana Partners as the Company's strategic transaction advisor to\nevaluate/implement creative ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia Biopharmaceuticals\n, Inc. (OTCQB: \"ABPI\").\n\nFor further information on the Company, please visit: http://www.Biovest.com\n\nForward-Looking ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (93%)",
  "headline": [
   "Biovest Retains Ferghana Partners to Evaluate Strategic Transactions"
  ],
  "length": [
   "790 words"
  ]
 },
 {
  "content": "Copyright 2012 Comtex News Network, Inc.\n                              All Rights Reserved\n                       Copyright 2012 TheFlyOnTheWall.com\n\n                              Theflyonthewall.com\n\n      This content is provided to LexisNexis by Comtex News Network, Inc.\n\n                       May 16, 2012 Wednesday 9:48 AM EST\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)\n\nPUB-COMPANY:\n\nAccentia Biopharmaceuticals Inc; Accentia Biopharmaceuticals Inc\n\nCOMPANY-TERMS:\n\nAccentia Biopharmaceuticals Inc ABPI (NASDAQ GM) SEDOL: 2964955 SIC: 2834 UNITED\nSTATES",
  "headline": [
   "BVTI, ABPI: Hot Stocks"
  ],
  "length": [
   "80  words"
  ]
 },
 {
  "content": "Copyright 2012 Espicom Business Intelligence\n                              All Rights Reserved\n                                Cancer Drug News\n\n                                  May 14, 2012\n\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "section": [
   "NEWS"
  ],
  "headline": [
   "Biovest to seek European marketing approval for BiovaxID"
  ],
  "length": [
   "173  words"
  ]
 },
 {
  "content": "Copyright 2012 Close-Up Media, Inc.\n                              All Rights Reserved\n\n\n\n                            Health & Beauty Close-up\n\n                             May 10, 2012 Thursday\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "headline": [
   "Biovest to Present at Cancer Immunotherapy Leaders Forum"
  ],
  "length": [
   "104  words"
  ]
 },
 {
  "content": "Copyright 2012 Close-Up Media, Inc.\n                              All Rights Reserved\n\n\n\n                            Health & Beauty Close-up\n\n                             May 9, 2012 Wednesday\n\n\n\nBODY:\n\nAccentia Biopharmaceuticals, Inc. announced that the Company and physicians from\nJohns Hopkins University co-hosted a meeting with prospective clinical trial\ninvestigators at the ...\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (93%)",
  "headline": [
   "Accentia Biopharmaceuticals Holds Investigator Meeting in Preparation\nfor New Multiple Sclerosis Drug Study for Cyrevia"
  ],
  "length": [
   "371  words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                  May 9, 2012\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Offering $5 Million of Securities"
  ],
  "length": [
   "497 words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                         May 7, 2012 Monday 5:15 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB: \"BVTI\"), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB: \"ABPI\"), today announced that Biovest\nwill present at the Immunotherapy Leaders' Forum 2012 being held May ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia Biopharmaceuticals\n, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (93%)",
  "headline": [
   "Biovest to Present at Cancer Immunotherapy Leaders Forum"
  ],
  "length": [
   "593 words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla."
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                        May 4, 2012 Friday 12:45 PM GMT\n\n\n\n\nBODY:\n\nAccentia Biopharmaceuticals, Inc. (OTCQB:ABPI) today announced that the Company\nand leading physicians from Johns Hopkins University co-hosted a meeting with\nprospective ...\n\n...REMS) to enhance patient safety by ensuring appropriate patient selection,\nsupportive care, and tracking of outcomes data.\n\nAbout Accentia Biopharmaceuticals, Inc.\n\nHeadquartered in Tampa, Florida, Accentia Biopharmaceuticals, Inc. (OTCQB:\n\"ABPI\") is committed to advancing the autoimmune disease therapy, Cyrevia(TM)\n(formerly Revimmune(TM)), as a comprehensive system of ...\n\nAccentia Biopharmaceuticals, Inc.:\nDouglas Calder, 813-864-2554, ext.258\nVice President, Strategic Planning & Capital Markets\ndwcalder@...\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (93%); BAXTER HEALTHCARE CORP (60%)",
  "headline": [
   "Accentia Biopharmaceuticals Conducts Investigator Meeting in\nPreparation for New Multiple Sclerosis Drug Study for Cyrevia(TM)"
  ],
  "length": [
   "962 words"
  ]
 },
 {
  "content": "Copyright 2012 Espicom Business Intelligence\n                              All Rights Reserved\n                            Anti-Infective Drug News\n\n                                 April 24, 2012\n\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "section": [
   "NEWS"
  ],
  "headline": [
   "Biovest/USAMRIID enter CRADA to develop novel bioreactor systems"
  ],
  "length": [
   "127  words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                       April 23, 2012 Monday 12:45 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that Biovest\nand the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)\nhave entered into a ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia Biopharmaceuticals\n, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "headline": [
   "Biovest and U.S. Army Enter into Collaborative Agreement to Develop\nNovel Bioreactor Systems as Platform Technology for Production of Anti-Viral\nVaccines and Drugs"
  ],
  "length": [
   "1108 words"
  ]
 },
 {
  "dateline": [
   "WASHINGTON, DC"
  ],
  "content": "Copyright 2012 States News Service\n                              States News Service\n\n                             April 16, 2012 Monday\n\n\n\n\n\nBODY:\n\n...TRUST MD 8.01,9.01 04/06/12 ACCELERA INNOVATIONS, INC. DE 1.01,2.01,5.06,9.01\n08/22/11 AMEND ACCENTIA BIOPHARMACEUTICALS INC FL 5.02 02/29/12 AMEND Accenture\nplc L2 8.01,9.01 04/13/12 ACCENTURE SCA ...",
  "headline": [
   "SEC NEWS DIGEST ISSUE 2012-73 APRIL 16, 2012"
  ],
  "length": [
   "4070 words"
  ],
  "byline": [
   "States News Service"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 April 16, 2012\n\n\n\n\nBODY:\n\n...\nThe\u00a0Board\u00a0of\u00a0Directors\u00a0of\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.,\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMA: Board OKs Compensation Arrangement for Execs."
  ],
  "length": [
   "559 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 April 16, 2012\n\n\n\n\nBODY:\n\n...\nAt\u00a0the\u00a0annual meeting\u00a0of\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.'s\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMA: Five Directors Elected at Annual Meeting"
  ],
  "length": [
   "385 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 April 16, 2012\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "BIOVEST INTERNATIONAL: Eight Directors Elected at Annual Meeting"
  ],
  "length": [
   "590 words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                      April 10, 2012 Tuesday 10:15 AM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that Biovest is\nseeking marketing approval in Canada for BiovaxID\u00ae, its personalized cancer ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia\nBiopharmaceuticals, Inc. (OTCQB: ABPI).\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (91%); M D\nANDERSON CANCER CENTER (54%)",
  "headline": [
   "Biovest to Seek Marketing Approval for BiovaxID\u00ae Personalized Lymphoma\nCancer Vaccine in Canada",
   "First vaccine to ever seek approval as blood cancer treatment"
  ],
  "length": [
   "1529 words"
  ]
 },
 {
  "content": "Copyright 2012 Espicom Business Intelligence\n                              All Rights Reserved\n                                Cancer Drug News\n\n                                 April 10, 2012\n\n\n\n\nCOMPANY:\n\nACCENTIA BIOPHARMACEUTICALS INC (91%)",
  "section": [
   "NEWS"
  ],
  "headline": [
   "Biovest to seek Canadian marketing approval for BiovaxID"
  ],
  "length": [
   "294  words"
  ]
 },
 {
  "dateline": [
   "TAMPA, FL & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                       April 3, 2012 Tuesday 12:45 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB:BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB:ABPI), today announced the\ninternational members of its Scientific Advisory Board (SAB) comprised of key\nopinion leaders from prestigious ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia Biopharmaceuticals\n, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (91%); BAYER AG\n(83%); NOVARTIS AG (83%); BAYER CORP (61%); SANOFI SA (58%); GLAXOSMITHKLINE PLC\n(...",
  "headline": [
   "Biovest Announces International Members of its Cancer Vaccine\nScientific Advisory Board"
  ],
  "length": [
   "1151 words"
  ]
 },
 {
  "content": "Copyright 2012 Close-Up Media, Inc.\n                              All Rights Reserved\n\n\n                         Professional Services Close-Up\n\n                              April 2, 2012 Monday\n\n\n\nBODY:\n\n...Investigation by Universities/Institutes\n\n-Companies Involved in Sinusitis Therapeutics Development\n\n-GlaxoSmithKline plc\n\n-PARI Pharma GmbH\n\n-Accentia Biopharmaceuticals, Inc.\n\n-SCOLR Pharma, Inc.\n\n-Bionorica AG\n\n-Mayne Pharma Limited\n\n-Sinusitis - Therapeutics Assessment\n\n-Assessment by Monotherapy Products\n\n-...\n\nCOMPANY:\n\nGLAXOSMITHKLINE PLC (82%); SCOLR PHARMA INC (82%); HOSPIRA AUSTRALIA PTY LTD\n(66%); ACCENTIA BIOPHARMACEUTICALS INC (66%)",
  "headline": [
   "Research and Markets Adds Report: Sinusitis - Pipeline Review, H1 2012"
  ],
  "length": [
   "390  words"
  ]
 },
 {
  "dateline": [
   "DUBLIN"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                       March 30, 2012 Friday 11:59 AM GMT\n\n\n\n\nBODY:\n\n...\nCell Therapeutics, Inc.\nGenmab A/S\nCelgene Corporation\nInNexus Biotechnology Inc.\nMethylGene Inc\nCuris, Inc.\nAccentia Biopharmaceuticals, Inc.\nAllos Therapeutics, Inc\nTelik, Inc.\nPharmacyclics, Inc.\nMorphoSys AG\nGreen Cross Corporation\nInnate Pharma SA\n...\n\nCOMPANY:\n\n...LTD (60%); SPECTRUM PHARMACEUTICALS INC (60%); CURIS INC (60%); PHARMACYCLICS\nINC (60%); CELGENE CORP (60%); ACCENTIA BIOPHARMACEUTICALS INC (60%); TELIK INC\n(60%); GENMAB AS (60%); MEDIMMUNE INC (51%)",
  "headline": [
   "Research and Markets: B-Cell Lymphomas - Pipeline Review, H1 2012"
  ],
  "length": [
   "614 words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                      March 27, 2012 Tuesday 12:15 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB:BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB:ABPI), today announced that Biovest has\nformally established its Scientific Advisory Board (SAB) comprised of key\nopinion leaders from ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia\nBiopharmaceuticals, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); BIOINFORMATICS LLC (92%); ACCENTIA\nBIOPHARMACEUTICALS INC (91%); M D ANDERSON CANCER CENTER (58%)",
  "headline": [
   "Biovest Establishes World Class Scientific Advisory Board Comprised of\nKey Opinion Leaders in the Fields of Cancer Immunotherapy, Bioinformatics and\nCell Culture Systems"
  ],
  "length": [
   "1229 words"
  ]
 },
 {
  "dateline": [
   "DUBLIN"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                      March 21, 2012 Wednesday 5:32 PM GMT\n\n\n\n\nBODY:\n\n...\nLimited\nNovartis AG\nCephalon, Inc.\nPfizer Inc.\nCelgene Corporation\nBayer AG\nIMMUNOMEDICS, INC\nMethylGene Inc\nAccentia Biopharmaceuticals, Inc.\nPharmacyclics, Inc.\nInnate Pharma SA\nMemgen, LLC.\nAscenta Therapeutics, Inc.\nS-BIO Pte Ltd\nCureTech ...\n\nCOMPANY:\n\n...INC (63%); INNATE PHARMA SA (63%); PHARMACYCLICS INC (63%); CELGENE CORP\n(63%); AGENUS INC (63%); ACCENTIA BIOPHARMACEUTICALS INC (63%); TAKEDA\nPHARMACEUTICAL CO LTD (63%); IMMUNOMEDICS INC (63%); GILEAD SCIENCES INC (63%)",
  "headline": [
   "Research and Markets: Follicular Lymphoma - Pipeline Review, H1 2012"
  ],
  "length": [
   "502 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 March 21, 2012\n\n\n\n\nBODY:\n\n...\n\"BVTI\",\u00a0and\u00a0is\u00a0a\u00a0majority-owned\u00a0subsidiary\u00a0of\u00a0Accentia\nBiopharmaceuticals,\u00a0Inc.\u00a0(OTCQB:\u00a0\"ABPI\").\n...",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "AMERICAN AXLE: Incurs $1.5 Million Net Loss in Dec. 31 Quarter"
  ],
  "length": [
   "389 words"
  ]
 },
 {
  "content": "Troubled Company Reporter\nCopyright  1994 - 2012  Bankruptcy Creditors' Service, Inc. & Beard Group, Inc.\n                              All Rights Reserved\n\n                           Troubled Company Reporter\n\n                                 March 20, 2012\n\n\n\n\nBODY:\n\n...\nAccentia\u00a0Biopharmaceuticals,\u00a0Inc.,\u00a0filed\u00a0its\u00a0quarterly\u00a0report\u00a0on\nHeadquartered\u00a0in\u00a0Tampa,\u00a0Florida,\u00a0Accentia\u00a0Biopharmaceuticals,\u00a0Inc.\n...\n\nPUB-COMPANY:\n\nAccentia BioPharmaceuticals Inc",
  "section": [
   "Vol. 16 ISSN: 1520-9474"
  ],
  "headline": [
   "ACCENTIA BIOPHARMA: Reports $660,500 Net Income in Dec. 31 Quarter"
  ],
  "length": [
   "551 words"
  ]
 },
 {
  "dateline": [
   "TAMPA, Fla. & MINNEAPOLIS"
  ],
  "content": "Copyright 2012 Business Wire, Inc.\n                                 Business Wire\n\n                      March 15, 2012 Thursday 1:30 PM GMT\n\n\n\n\nBODY:\n\nBiovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of\nAccentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that an article\nwas published in Drug Discovery News, reporting on the promise of Biovest's ...\n\n...Biovest is publicly-traded on the OTCQB(TM) Market with the stock-ticker\nsymbol \"BVTI\", and is a majority-owned subsidiary of Accentia Biopharmaceuticals\n, Inc. (OTCQB: \"ABPI\").\n\nFor further information, please visit: http://www.biovest.com\n\nForward-Looking Statements:\n\nStatements ...\n\nCOMPANY:\n\nBIOVEST INTERNATIONAL INC (93%); ACCENTIA BIOPHARMACEUTICALS INC (91%); M D\nANDERSON CANCER CENTER (56%)",
  "headline": [
   "BiovaxID\u00ae Personalized Lymphoma Vaccine is Featured in Article\nPublished in Drug Discovery News"
  ],
  "length": [
   "1034 words"
  ]
 }
]